Valuation: argenx SE

Market Cap 62.49B 54.5B 51.46B 46.73B 87.55B 5,997B 87.91B 616B 238B 3,049B 235B 230B 9,810B P/E 2026 *
32.5x
P/E 2027 * 27.1x
Enterprise Value 58.79B 51.27B 48.41B 43.96B 82.36B 5,641B 82.7B 580B 224B 2,868B 221B 216B 9,228B EV / Sales 2026 *
9.38x
EV / Sales 2027 * 7.39x
Free-Float
99.99%
Yield 2026 *
0.04%
Yield 2027 * 0.08%
1 day+0.39%
1 week+2.06%
Current month-0.48%
1 month+0.16%
3 months+14.24%
6 months+45.28%
Current year+21.57%
1 week 844
Extreme 844
876.4
1 month 842
Extreme 842
925
Current year 568.4
Extreme 568.4
925
1 year 568.4
Extreme 568.4
925
3 years 271
Extreme 271
925
5 years 224.1
Extreme 224.1
925
10 years 12.5
Extreme 12.5
925
Manager TitleAgeSince
Chief Executive Officer 47 2026-05-05
Director of Finance/CFO 56 2021-05-31
Chief Tech/Sci/R&D Officer - 2014-12-31
Director TitleAgeSince
Chairman 54 2026-05-05
Director/Board Member 76 2015-05-12
Director/Board Member 65 2016-04-27
Date Insider Type Main position Quantity % Market Cap. Importance
11/23/25 Sell

Chief Executive Officer

2,000 0.0032%
11/23/25 Sell

Director

4,680 0.0076%
11/23/25 Exercice

Director

4,680 0.0076%
Change 5-day change 1-year change 3-year change Capi.($)
+0.39%+2.06%+40.91%+78.49% 62.32B
-0.31%+5.79%+48.93%+97.53% 70.89B
-3.21%-7.27%-17.73%+351.98% 27.07B
+0.50%+7.13%+29.43%+15.48% 26.2B
-2.64%-0.69%-0.26%-11.90% 24.78B
+0.71%+8.03%+27.22%-13.18% 20.59B
-1.26%-7.81%+169.33%+302.38% 15.52B
-0.22%+3.99%+44.28%+173.35% 14.49B
+0.73%+1.71%-7.18%+886.19% 14.14B
+0.04%-0.77%-9.49%+456.14% 14.06B
Average -0.53%+1.32%+32.54%+233.65% 29.01B
Weighted average by Cap. -0.46%+1.29%+34.13%+163.13%

Financials

2026 *2027 *
Net sales 6.27B 5.46B 5.16B 4.68B 8.78B 601B 8.81B 61.8B 23.85B 306B 23.54B 23.02B 984B 7.62B 6.65B 6.28B 5.7B 10.68B 731B 10.72B 75.18B 29.01B 372B 28.63B 28B 1,196B
Net income 1.14B 997M 941M 855M 1.6B 110B 1.61B 11.28B 4.35B 55.77B 4.29B 4.2B 179B 2.38B 2.07B 1.96B 1.78B 3.33B 228B 3.34B 23.45B 9.05B 116B 8.93B 8.73B 373B
Net Debt -3.7B -3.23B -3.05B -2.77B -5.19B -355B -5.21B -36.53B -14.1B -181B -13.91B -13.6B -581B -6.19B -5.39B -5.09B -4.62B -8.66B -593B -8.7B -61B -23.54B -302B -23.23B -22.72B -971B
Logo argenx SE
argenx SE is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx SE aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx SE developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises.
Employees
1,863
Date Price Change Volume
26-09-18 €871.40 +0.39% 203,162
26-09-17 €868.00 +2.29% 60,610
26-09-16 €848.60 -1.19% 62,261
26-09-15 €858.80 -1.04% 44,698
26-09-14 €867.80 +1.64% 53,326
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
999.31USD
Average target price
1,178.77USD
Spread / Average Target
+17.96%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ARGX Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!